Form 4 for KNSA Kiniksa Pharmaceuticals International, plc
Accepted 2022-03-18 00:00:00 ET · period of report 2021-07-15 · accession 0001179110-22-002324 · SEC index · Original document
Summary rows
Aggregated the way they appear in lists: one row per insider, transaction code and security table.
| X | Filed | Traded | Ticker | Insider | Title | Type | Price | Qty | Owned | ΔOwn | Value |
|---|---|---|---|---|---|---|---|---|---|---|---|
| D | 2022-03-18 | 2022-03-16 | KNSA | Tessari Eben | COO | F - Tax | $10.13 | -681 | 109.1K | -0.6% | -$6,899 |
| D | 2022-03-18 | 2022-03-16 | KNSA | Tessari Eben | COO | M - OptEx | — | +1,964 | 109.7K | +2% | — |
| DM | 2022-03-18 | 2021-07-15+ | KNSA | Tessari Eben | COO | A - Grant | $10.51 | +1,838 | 106.8K | +2% | +$19.3K |
| D | 2022-03-18 | 2022-03-16 | KNSA | Tessari Eben | COO | M - OptEx | $0.00 | -1,964 | 5,892 | -25% | $0 |
Purchase Sale Sale after option exercise All abbreviations
Every reported transaction
| # | Table | Security | Date | Code | A/D | Shares | Price | Owned after | Own | Exercise / expiry | Underlying | Footnotes |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | Common | Class A Common Share | 2022-03-16 | F | D | 681 | $10.13 | 109,063 | D | — | — | |
| 2 | Common | Class A Common Share | 2022-03-16 | M | A | 1,964 | — | 109,744 | D | — | — | (F3) Each Restricted Share Unit (RSU) represents a contingent right to receive one Class A Common Share of the Issuer. |
| 3 | Common | Class A Common Share | 2022-01-15 | A | A | 970 | $9.63 | 107,780 | D | — | — | |
| 4 | Common | Class A Common Share | 2021-07-15 | A | A | 868 | $11.49 | 106,810 | D | — | — | |
| 5 | Derivative | Restricted Share Unit | 2022-03-16 | M | D | 1,964 | $0.00 | 5,892 | D | — · — to — | 1,964 Class A Common Share | (F3) Each Restricted Share Unit (RSU) represents a contingent right to receive one Class A Common Share of the Issuer. (F4) The RSUs vest over a four-year period, with 25% of the RSUs vesting on each yearly anniversary of the date of grant, March 16, 2021. |